Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary05/19/2011
MISGAV, Israel and VIENNA, Va., May 19, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) today announced that Andrew L. Pearlman, Ph.D., the Company's President and CEO, will present a corporate overview at the 10 th Annual Israeli Life Sciences Industry Biomed 2011
Toggle Summary05/12/2011
MISGAV, Israel & VIENNA, Va., May 12, 2011 (BUSINESS WIRE) -- Medgenics, Inc. (NYSE Amex: MDGN and MDGN.W and London Stock Exchange-AIM: MEDG and MEDU) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their
Toggle Summary05/04/2011
MISGAV, ISRAEL and VIENNA, VA, May 04, 2011 (MARKETWIRE via COMTEX) -- Medgenics, Inc. (NYSE Amex: MDGN) (NYSE Amex: MDGN.W) (AIM: MEDG) (AIM: MEDU), the company that has developed a novel technology for the sustained manufacture and delivery of therapeutic proteins continuously in patients using
Toggle Summary05/03/2011
MISGAV, ISRAEL and VIENNA, VA, May 03, 2011 (MARKETWIRE via COMTEX) -- Medgenics, Inc. (NYSE Amex: MDGN) (NYSE Amex: MDGN.W) (AIM: MEDG) (AIM: MEDU), the company that has developed a novel technology for the sustained manufacture and delivery of therapeutic proteins continuously in patients using
Toggle Summary04/19/2011
MISGAV, ISRAEL and VIENNA, VA, Apr 19, 2011 (MARKETWIRE via COMTEX) -- Medgenics, Inc. (NYSE Amex: MDGN) (NYSE Amex: MDGN.W) (AIM: MEDG) (AIM: MEDU), the company that has developed a novel technology for the sustained manufacture and delivery of therapeutic proteins continuously in patients using
Toggle Summary04/08/2011
MISGAV, ISRAEL and VIENNA, VA, Apr 08, 2011 (MARKETWIRE via COMTEX) -- Medgenics, Inc. (NYSE Amex: MDGN) (NYSE Amex: MDGN.W) (AIM: MEDG) (AIM: MEDU), the company that has developed a novel technology for the sustained manufacture and delivery of therapeutic proteins continuously in patients using
Toggle Summary02/15/2011
Toggle Summary11/22/2010
  Misgav, Israel and London, UK - November 22, 2010 - Medgenics (AIM: MEDU, MEDG) announces that it has finalized a 6-month extension of its agreement with its major international pharmaceutical company collaborator to continue the joint development of Factor VIII Biopump.
Toggle Summary11/08/2010
Misgav, Israel and London, UK -  8 November 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that has been awarded a cash
Toggle Summary10/27/2010